Trastuzumab (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Trastuzumab" in Polish language version.

refsWebsite

Global rank Polish rank

17nih.gov

4^th place

7^th place

14doi.org

2^nd place

6^th place

7web.archive.org

1^st place

2bpac.org.nz

low place

2alivia.org.pl

low place

3,582^nd place

1drugbank.ca

4,294^th place

205^th place

1healthlifeandstuff.com

low place

1nature.com

234^th place

204^th place

1dakousa.com

low place

1ventanamed.com

low place

1twinkletwinkles.com

low place

1health.gov.au

low place

1nzherald.co.nz

435^th place

1,391^st place

1bbc.co.uk

8^th place

22^nd place

1nice.org.uk

3,258^th place

2,944^th place

1cbc.ca

115^th place

666^th place

1scoop.co.nz

3,973^rd place

low place

1pharmindex.pl

low place

8,567^th place

1informapharmascience.com

low place

1healthvalue.net

low place

alivia.org.pl

Troponina I – Pomocny marker w leczeniu herceptyną. www.alivia.org.pl. [dostęp 2015-05-13]. [zarchiwizowane z tego adresu (2015-05-19)].
Nowe, obiecujące schematy w leczeniu raka piersi HER2+++. www.alivia.org.pl. [dostęp 2015-05-25]. [zarchiwizowane z tego adresu (2015-05-25)].

bbc.co.uk

news.bbc.co.uk

The trastuzumab judgement. BBC News, 2006-04-12. [dostęp 2006-12-01].

bpac.org.nz

cbc.ca

Ontario to pay for cancer drugs. Canadian Broadcasting Corporation, 2005-07-22. [dostęp 2006-12-01]. [zarchiwizowane z tego adresu (2007-03-16)].

dakousa.com

Dako HercepTest.

doi.org

S Ménard, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. „Oncogene”. 22 (42), s. 6570–6578, 2003. DOI: 10.1038/sj.onc.1206779. PMID: 14528282.
T Kute, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP. Development of herceptin resistance in breast cancer cells. „Cytometry”. 57A (2), s. 86–93, 2004. DOI: 10.1002/cyto.a.10095. PMID: 14750129.
CA Hudis. Trastuzumab--mechanism of action and use in clinical practice. „N Engl J Med.”. 357 (1), s. 39–51, 2007. DOI: 10.1056/NEJMra043186. PMID: 17611206.
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. „Nat Med”. 6 (4), s. 443–446, 2000. DOI: 10.1038/74704. PMID: 10742152.
J Bange, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. „Nature Medicine”. 7 (5), s. 548–552, 2001. DOI: 10.1038/87872. PMID: 11329054.
AR Tan, Swain SM. Ongoing adjuvant trials with trastuzumab in breast cancer. „Seminars in Oncology”. 30 (5 Suppl 16), s. 54–64, 2002. DOI: 10.1053/j.seminoncol.2003.08.008. PMID: 14613027.
EH Romond, Perez EA, Bryant J, et al.. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. „New England Journal of Medicine”. 353 (16), s. 1673–1684, 2005. DOI: 10.1056/NEJMoa052122. PMID: 16236738.
MJ Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. „New England Journal of Medicine”. 353 (16), s. 1659–1672, 2005. DOI: 10.1056/NEJMoa052306. PMID: 16236737.
P Littlejohns. Trastuzumab for early breast cancer: evolution or revolution?. „Lancet Oncology”. 7 (1), s. 22–23, 2006. DOI: 10.1016/S1470-2045(05)70533-7. PMID: 16408378.
Fleck L. The costs of caring: Who pays? Who profits? Who panders?. „Hastings Cent Rep”. 36 (3), s. 13–17, 2006. DOI: 10.1353/hcr.2006.0040. PMID: 16776017.
Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. „Int J Gynaecol Obstet”. 102 (2), s. 128–131, 2008. DOI: 10.1016/j.ijgo.2008.04.008. PMID: 18555254.

dx.doi.org

Antonio C.A.C. Wolff Antonio C.A.C. i inni, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, „Archives of Pathology & Laboratory Medicine”, 131 (1), 2007, s. 18–43, DOI: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2, PMID: 19548375 .
Bettina G.B.G. Papouchado Bettina G.B.G. i inni, Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility, „The American Journal of Surgical Pathology”, 34 (6), 2010, s. 767–776, DOI: 10.1097/PAS.0b013e3181d96231, PMID: 20421783 .
TomásT. García-Caballero TomásT. i inni, Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens, „Histopathology”, 56 (4), 2010, s. 472–480, DOI: 10.1111/j.1365-2559.2010.03503.x, PMID: 20459554, PMCID: PMC2855864 .

drugbank.ca

Trastuzumab, [w:] DrugBank, University of Alberta, DB00072 [dostęp 2021-07-27] (ang.).

health.gov.au

Listing of Herceptin on PBS. Australian Government, Dept of Health and Ageing, 2006-10-01. [dostęp 2010-08-19]. [zarchiwizowane z tego adresu (2009-09-12)].

healthlifeandstuff.com

Herceptin or Trastuzumab: Efficacy, Side Effects. Health and Life.

healthvalue.net

Pertuzumab.

informapharmascience.com

Vecchione L. Novel investigational drugs for gastric cancer. Expert Opin Investig Drugs. 2009 May 26. [Epub ahead of publication]. Review /article.

nature.com

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Nature [online], nature.com [dostęp 2024-04-26] (ang.).

nice.org.uk

Update on Herceptin appraisal. National Institute for Health and Clinical Excellence. [dostęp 2006-12-01]. [zarchiwizowane z tego adresu (2006-12-13)].

nih.gov

ncbi.nlm.nih.gov

RitaR. Nahta RitaR., Francisco J.F.J. Esteva Francisco J.F.J., HER-2-targeted therapy: lessons learned and future directions, „Clinical Cancer Research: An Official Journal of the American Association for Cancer Research”, 9 (14), 2003, s. 5078–5084, PMID: 14613984 .
S Ménard, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. „Oncogene”. 22 (42), s. 6570–6578, 2003. DOI: 10.1038/sj.onc.1206779. PMID: 14528282.
T Kute, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP. Development of herceptin resistance in breast cancer cells. „Cytometry”. 57A (2), s. 86–93, 2004. DOI: 10.1002/cyto.a.10095. PMID: 14750129.
CA Hudis. Trastuzumab--mechanism of action and use in clinical practice. „N Engl J Med.”. 357 (1), s. 39–51, 2007. DOI: 10.1056/NEJMra043186. PMID: 17611206.
J Albanell, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. „Advances in Experimental Medicine and Biology”. 532, s. 253–268, 2003. PMID: 12908564.
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. „Nat Med”. 6 (4), s. 443–446, 2000. DOI: 10.1038/74704. PMID: 10742152.
J Bange, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. „Nature Medicine”. 7 (5), s. 548–552, 2001. DOI: 10.1038/87872. PMID: 11329054.
DJ Slamon, Clark GM. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. „Science”. 235 (4785), s. 177–182, 1987. PMID: 3798106.
AR Tan, Swain SM. Ongoing adjuvant trials with trastuzumab in breast cancer. „Seminars in Oncology”. 30 (5 Suppl 16), s. 54–64, 2002. DOI: 10.1053/j.seminoncol.2003.08.008. PMID: 14613027.
Antonio C.A.C. Wolff Antonio C.A.C. i inni, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, „Archives of Pathology & Laboratory Medicine”, 131 (1), 2007, s. 18–43, DOI: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2, PMID: 19548375 .
Bettina G.B.G. Papouchado Bettina G.B.G. i inni, Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility, „The American Journal of Surgical Pathology”, 34 (6), 2010, s. 767–776, DOI: 10.1097/PAS.0b013e3181d96231, PMID: 20421783 .
TomásT. García-Caballero TomásT. i inni, Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens, „Histopathology”, 56 (4), 2010, s. 472–480, DOI: 10.1111/j.1365-2559.2010.03503.x, PMID: 20459554, PMCID: PMC2855864 .
EH Romond, Perez EA, Bryant J, et al.. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. „New England Journal of Medicine”. 353 (16), s. 1673–1684, 2005. DOI: 10.1056/NEJMoa052122. PMID: 16236738.
MJ Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. „New England Journal of Medicine”. 353 (16), s. 1659–1672, 2005. DOI: 10.1056/NEJMoa052306. PMID: 16236737.
P Littlejohns. Trastuzumab for early breast cancer: evolution or revolution?. „Lancet Oncology”. 7 (1), s. 22–23, 2006. DOI: 10.1016/S1470-2045(05)70533-7. PMID: 16408378.
Fleck L. The costs of caring: Who pays? Who profits? Who panders?. „Hastings Cent Rep”. 36 (3), s. 13–17, 2006. DOI: 10.1353/hcr.2006.0040. PMID: 16776017.
Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. „Int J Gynaecol Obstet”. 102 (2), s. 128–131, 2008. DOI: 10.1016/j.ijgo.2008.04.008. PMID: 18555254.

nzherald.co.nz

Breast cancer drug to remain unfunded. New Zealand Herald, 2006-10-16. [dostęp 2006-12-01].

pharmindex.pl

baza.pharmindex.pl

Pharmindex – internetowy spis leków. UMB Medica Polska. [dostęp 2010-08-19]. (pol.).

scoop.co.nz

Will Herceptin Media Blitz Help Or Harm Patients?. Scoop, 2006-02-14. [dostęp 2006-12-01].

twinkletwinkles.com

Herceptin Benefits and Risks. [dostęp 2010-08-19]. [zarchiwizowane z tego adresu (2009-03-28)]. oraz Misleading press coverage of trastuzumab. [dostęp 2010-08-19]. [zarchiwizowane z tego adresu (2010-07-20)].

ventanamed.com

Ventana Pathway.

web.archive.org

https://web.archive.org/web/20080227143935/http://www.sws-pct.nhs.uk/PEC/2005/061205/Enc_08.pdf SWS-PCT.
Herceptin Benefits and Risks. [dostęp 2010-08-19]. [zarchiwizowane z tego adresu (2009-03-28)]. oraz Misleading press coverage of trastuzumab. [dostęp 2010-08-19]. [zarchiwizowane z tego adresu (2010-07-20)].
Listing of Herceptin on PBS. Australian Government, Dept of Health and Ageing, 2006-10-01. [dostęp 2010-08-19]. [zarchiwizowane z tego adresu (2009-09-12)].
Update on Herceptin appraisal. National Institute for Health and Clinical Excellence. [dostęp 2006-12-01]. [zarchiwizowane z tego adresu (2006-12-13)].
Ontario to pay for cancer drugs. Canadian Broadcasting Corporation, 2005-07-22. [dostęp 2006-12-01]. [zarchiwizowane z tego adresu (2007-03-16)].
Troponina I – Pomocny marker w leczeniu herceptyną. www.alivia.org.pl. [dostęp 2015-05-13]. [zarchiwizowane z tego adresu (2015-05-19)].
Nowe, obiecujące schematy w leczeniu raka piersi HER2+++. www.alivia.org.pl. [dostęp 2015-05-25]. [zarchiwizowane z tego adresu (2015-05-25)].